All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Menstruation, Menopause, and Hormone Replacement Therapy for Women

Peter Attia MD

2,441,925 views views on YouTubeWatch on YouTube

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Menopause HRTMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 3 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Menstruation, Menopause, and Hormone Replacement Therapy for Women, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Menstruation, Menopause, and Hormone Replacement Therapy for Women should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Menstruation, Menopause, and Hormone Replacement Therapy for Women" from Peter Attia MD. We read the clip as a Menopause HRT claim about Menopause HRT, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Perimenopause can begin 8-10 years before the last period, with erratic hormone fluctuations causing a wide range of symptoms.

The reason this review is not generic is the source wording and the canonical claim label "hrt menopause menstruation menopause and hormone replacement therapy for women." In this clip, the useful excerpt is: "Perimenopause can begin 8-10 years before the last period, with erratic hormone fluctuations causing a wide range of symptoms." That wording changes the review because it points to Menopause HRT evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Understanding weight gain at menopause (2012), Management of obesity in menopause (2024), and Management of menopause: a view towards prevention (2022), plus the creator's own wording. Menopause HRT decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Transdermal estrogen is generally preferred over oral for its better safety profile, avoiding first-pass liver metabolism and reducing clot risk.
People who land here are usually comparing the Menopause HRT claim with hrt and menopause.
The strongest next step is to compare the claim with FormBlends' Menopause HRT guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Perimenopause can begin 8-10 years before the last period, with erratic hormone fluctuations causing a wide range of symptoms.

FormBlends verdict

Menopause HRT evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video is useful as a prompt for better questions, but it should not be treated as a personalized treatment plan.
  • Perimenopause can begin 8-10 years before the last period, with erratic hormone fluctuations causing a wide range of symptoms.
  • Transdermal estrogen is generally preferred over oral for its better safety profile, avoiding first-pass liver metabolism and reducing clot risk.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Perimenopause can begin 8-10 years before the last period, with erratic hormone fluctuations causing a wide range of symptoms.
  • Transdermal estrogen is generally preferred over oral for its better safety profile, avoiding first-pass liver metabolism and reducing clot risk.
  • The window of opportunity for HRT cardiovascular and bone benefits is within 10 years of menopause onset or before age 60.
  • Women can lose up to 20% of their bone density in the first 5-7 years after menopause due to estrogen withdrawal.
  • Micronized progesterone is preferred over synthetic progestins and offers additional benefits for sleep, mood, and potential neuroprotection.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

The Full Arc of Female Hormones: From Menstruation to Menopause

Peter Attia has a gift for taking deeply technical medical topics and making them accessible without dumbing them down. This conversation covers the entire hormonal journey women experience, from the onset of menstruation through the menopausal transition and into the decision about hormone replacement therapy. If you have ever wanted a single resource that connects all these dots, this is it.

The female reproductive hormone system is about more than reproduction. Estrogen, progesterone, and yes, testosterone operate throughout the body, affecting the brain, the cardiovascular system, bones, muscles, metabolism, and immune function. When these hormones fluctuate during the menstrual cycle, women experience predictable shifts in energy, mood, cognitive function, and physical performance. When they decline during menopause, the effects are systemic and often profoundly disruptive.

What Actually Happens During Perimenopause

Most women think of menopause as a single event, the cessation of periods. But the transition leading up to it, perimenopause, can begin 8 to 10 years before the last period. During this time, ovarian function becomes increasingly erratic. Some cycles produce normal amounts of estrogen and progesterone. Others produce wildly elevated estrogen with little progesterone. And some cycles produce almost nothing. This volatility, not the eventual decline, is what makes perimenopause so symptomatic for many women.

The symptoms of perimenopause read like a catalog of everything that can go wrong: hot flashes, night sweats, insomnia, anxiety, depression, brain fog, joint pain, weight gain (especially around the midsection), heart palpitations, headaches, and changes in menstrual bleeding. Many women spend years bouncing between specialists, getting treated for individual symptoms without anyone connecting them to the hormonal transition that is driving all of it.

Peter Attia emphasizes that perimenopause is dramatically underdiagnosed and undertreated. The average woman sees multiple providers and spends years dealing with these symptoms before anyone identifies perimenopause as the root cause. This is a systemic failure of medical education and clinical practice, not a personal failure of the women experiencing it.

The Cardiovascular Connection Most People Miss

One of the most important points in this conversation is the cardiovascular impact of estrogen loss. Premenopausal women have significantly lower rates of heart disease compared to men of the same age. This is largely attributable to estrogen's effects on blood vessel function, lipid metabolism, and inflammation. When estrogen declines during menopause, that cardiovascular protection disappears, and women's heart disease risk rises to match or exceed men's within about a decade.

This is not a minor consideration. Heart disease is the number one killer of women, and the menopausal transition is a critical window where the trajectory can be influenced. Hormone replacement therapy, when initiated within 10 years of menopause or before age 60, has been shown to reduce cardiovascular risk. Delay that initiation, and the benefit diminishes or potentially reverses. The timing matters enormously, and this nuance is often lost in the binary "HRT is good" or "HRT is bad" conversation.

Making Sense of HRT Options

The world of hormone replacement therapy can feel overwhelming. Estrogen comes in pills, patches, gels, creams, sprays, and pellets. Progesterone can be micronized (bioidentical) or synthetic. Testosterone may or may not be included. Doses vary. Delivery methods vary. And the research base for each combination is different.

Attia breaks down the key principles. Transdermal estrogen (patches, gels, or creams) is generally preferred over oral estrogen because it avoids first-pass liver metabolism, which reduces the risk of blood clots and may have a better overall safety profile. Micronized progesterone (brand name Prometrium, or compounded) is preferred over synthetic progestins like medroxyprogesterone acetate (Provera), which was the form used in the WHI study and is associated with a less favorable risk profile.

For women who still have a uterus, progesterone is necessary to protect the endometrial lining from estrogen-driven overgrowth. For women who have had a hysterectomy, progesterone may still be beneficial for its effects on sleep, mood, and neuroprotection, though this is an area of ongoing research.

Bones, Brain, and the Long Game

Bone density peaks in a woman's late 20s to early 30s and then gradually declines. After menopause, the rate of bone loss accelerates dramatically due to estrogen withdrawal. Within the first 5 to 7 years after menopause, women can lose up to 20% of their bone density. This is why osteoporosis disproportionately affects postmenopausal women, and why hip fractures in older women carry such a high mortality rate.

HRT is one of the most effective tools for preserving bone density during and after the menopausal transition. It does more than slow bone loss; it can actually maintain or increase bone mineral density when other interventions fall short. Combined with resistance training and adequate calcium and vitamin D intake, HRT creates a full strategy for skeletal health that extends well beyond menopause.

The cognitive effects of estrogen loss are gaining increasing attention in research. Estrogen has neuroprotective properties, supporting synaptic plasticity, mitochondrial function in brain cells, and the clearance of amyloid proteins that are associated with Alzheimer's disease. Women have roughly twice the risk of Alzheimer's compared to men, and the menopausal estrogen decline is a leading hypothesis for why. While HRT is not currently approved for cognitive protection, the emerging data is compelling enough that many researchers consider it a significant potential benefit of timely hormone therapy.

Practical Takeaways for Your Own Health

Attia's approach is characteristically systematic. If you are approaching or in perimenopause, get baseline labs that include estradiol, progesterone, FSH, LH, free and total testosterone, SHBG, DHEA-S, and a complete metabolic panel. Track your symptoms carefully, noting patterns in relation to your cycle if you still have one. This data will help you and your provider make informed decisions.

If you are considering HRT, start the conversation early. The window of opportunity for cardiovascular and bone benefits is time-sensitive. Waiting until you are 10 or more years past menopause may mean missing the period where HRT provides the most protection. Finding a provider who is knowledgeable about current HRT evidence, not still operating under the shadow of the 2002 WHI headlines, is worth the effort.

If HRT is not an option for you due to contraindications or personal choice, focus on the lifestyle interventions that can partially compensate: heavy resistance training for bone and muscle preservation, cardiovascular exercise for heart health, adequate protein and micronutrient intake, stress management, and quality sleep. These are not perfect substitutes for hormone therapy, but they are powerful tools in their own right.

Muscle health during and after menopause deserves more attention than it typically receives. Sarcopenia, the progressive loss of muscle mass and function, accelerates dramatically after menopause due to the combined effects of estrogen withdrawal, reduced physical activity, and inadequate protein intake. This is about more than looking different. Muscle mass directly impacts metabolic rate, blood sugar regulation, balance, fall prevention, and the ability to live independently as you age. Women who maintain muscle mass through resistance training and adequate protein have better metabolic profiles, lower fracture risk, and greater functional capacity well into their 70s and 80s.

The psychological effects of the menopausal transition are also worth addressing directly. Many women describe a loss of identity during this period, a sense that the person they were is slipping away. The combination of physical changes, cognitive shifts, mood instability, and sleep deprivation can erode confidence and self-image in ways that feel overwhelming. Understanding that these experiences have a physiological basis, that they are driven by measurable hormonal changes rather than personal weakness, can be genuinely liberating. It does not make the symptoms disappear, but it reframes them as something that can be addressed rather than something that must simply be endured.

Peter Attia also touches on the often-overlooked topic of sexual health during menopause. Vaginal atrophy, decreased lubrication, and reduced sensitivity are direct consequences of estrogen withdrawal and affect the majority of postmenopausal women. These symptoms do not improve on their own and typically worsen over time without treatment. Local vaginal estrogen, which delivers estrogen directly to the affected tissues with minimal systemic absorption, is one of the most effective and underused treatments available. Many women suffer in silence because they are embarrassed to bring it up, and many providers fail to ask about it. This needs to change.

The concept of hormone testing during perimenopause deserves clarification because it confuses many women and providers alike. Because hormone levels fluctuate dramatically during perimenopause, a single blood test often cannot definitively diagnose the transition. Your estradiol might be 200 one week and 50 the next. Your FSH might be elevated on one draw and normal on the next. This does not mean testing is useless, but it does mean that serial testing over time, combined with symptom assessment, provides a much better picture than a single snapshot. Some practitioners use saliva or dried urine testing for a broader hormone profile, though these methods are not universally accepted in mainstream medicine.

Why This Conversation Matters

The failure to adequately educate women about their own hormonal physiology has real consequences. Women suffer needlessly through perimenopause because no one tells them what is happening. They avoid HRT because of outdated fear. They lose bone, cardiovascular protection, and cognitive resilience because the medical system has not caught up to the evidence. Peter Attia's deep dive into this topic is a service to every woman who has been told to just deal with it, or worse, that what she is experiencing is not real. It is real. It is biological. And there are things you can do about it.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Peter Attia MD ·

2,441,925 views views on this video

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about perimenopause can begin 8-10 years before the last period, with?

Perimenopause can begin 8-10 years before the last period, with erratic hormone fluctuations causing a wide range of symptoms.

What does the video say about transdermal estrogen?

Transdermal estrogen is generally preferred over oral for its better safety profile, avoiding first-pass liver metabolism and reducing clot risk.

What does the video say about the window of opportunity for hrt cardiovascular?

The window of opportunity for HRT cardiovascular and bone benefits is within 10 years of menopause onset or before age 60.

What does the video say about women can lose up to 20% of their bone density?

Women can lose up to 20% of their bone density in the first 5-7 years after menopause due to estrogen withdrawal.

What does the video say about micronized progesterone?

Micronized progesterone is preferred over synthetic progestins and offers additional benefits for sleep, mood, and potential neuroprotection.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Not medical advice. This video was made by Peter Attia MD, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.